Table 1.
Clinical features of patients
| Items | Erlotinib Group (N = 108) | Gefinitib Group (N = 171) | P value |
|---|---|---|---|
| Age, y (%) | 0.719 | ||
| ≥ 60 | 45 (41.7%) | 75 (43.9%) | |
| < 60 | 63 (58.3%) | 96 (56.1%) | |
| Gender, n (%) | 0.343 | ||
| Male | 53 (49.1%) | 74 (43.3%) | |
| Female | 55 (50.9%) | 97 (56.7%) | |
| Smoking history a, n (%) | 0.359 | ||
| Never smoking | 70 (64.8%) | 120 (70.2%) | |
| Now/once smoking | 38 (35.2%) | 51 (29.8%) | |
| ECOG PS score, n (%) | 0.491 | ||
| 0-1 | 106 (98.1%) | 165 (96.5%) | |
| 2 | 2 (1.9%) | 6 (3.5%) | |
| Pathological type, n (%) | 1.000 | ||
| Adenocarcinoma | 98 (90.7%) | 156 (91.2%) | |
| Non adenocarcinoma | 10 (9.3%) | 15 (8.8%) | |
| Cancer stagingb, n (%) | 0.088 | ||
| Recurrent type c | 18 (16.7%) | 44 (25.7%) | |
| IIIb stage | 7 (6.5%) | 17 (9.9%) | |
| IV stage | 83 (76.9%) | 110 (64.3%) | |
| Cerebral metastasis before EGFR-TKIs use, n (%) | 24 (22.2%) | 22 (12.9%) | 0.047 |
| Previous treatment of cerebral metastasis, No. | — | ||
| WBRT + TKI | 14 | 11 | |
| Surgery + WBRT | 2 | 3 (1) | |
| WBRT + SRS | 4 | 5 | |
| None | 4 | 3 | |
| Cerebral metastasis number before EGFR-TKIs use, n | — | ||
| 1 | 2 | 3 | |
| 2-3 | 4 | 5 | |
| ≥ 4 | 18 | 14 | |
a Present smoker was defined as someone who had smoked more than 100 cigarettes in their lifetime but either currently being smoking or stopped smoking less than 1 year ago; former smoker was defined as someone who had smoked more than 100 cigarettes in their lifetime and stopped smoking at least 1 year ago; non-smoker was defined as having either smoked 100 or fewer cigarettes in their lifetime or had never smoked cigarettes
b American Joint Committee on Cancer staging system 7th edition
c Patients with stage I-IIIa NSCLC with systemic recurrence following definitive therapy that included surgical resection or radiotherapy